Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 29, 2013

Auxilium Snaps Up Urolology Therapeutics Firm Actient in $585M Deal

  • Auxilium Pharmaceuticals is slated to acquire urology therapeutics firm Actient Holdings in a $585 million up-front cash deal. Through this acquisition, Auxilium also expects to receive a tax benefit with a net value of around $60 million, at present.

    The Malvern, PA-based pharma’s acquisition of Actient will expand its specialty therapeutic offerings. Actient’s urology portfolio includes Edex®, an injectable drug for erectile dysfunction, among other drug and medical device offerings. Actient has a staff of 165, including 100 sales reps.

    Adrian Adams, Auxilium president and CEO, called the deal "a compelling fit from both a strategic and financial standpoint” because, he said in a statement, “the transaction creates a leading urology franchise with a diversified product portfolio and sales force leverage that is well positioned for growth of our current portfolio as we pursue the potential expansion of our label for Xiaflex® in Peyronie's disease.”



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »